US44486Q1031
© Globe Newswire
22.12.2025
HUMA
LISTED
NASDAQ
Humacyte Announces Publication of Long-Term Safety and Efficacy Results of Symvess® in Extremity Trauma Repair
News Preview
- Results published in Journal of Vascular Surgery Cases, Innovations and Techniques (JVS-CIT) - ...
Themefolio
Profiler
Peergroup
© Globe Newswire
16.12.2025
HUMA
LISTED
NASDAQ
Humacyte Announces Credit Facility of Up to $77.5 Million with Avenue Capital
News Preview
DURHAM, N.C., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that it has entered into a credit facility with Avenue Venture Opportunities Fund II, L.P., a fund of Avenue Capital G...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.11.2025
HUMA
LISTED
NASDAQ
Humacyte Announces Third Quarter 2025 Financial Results and Provides Business Update
News Preview
- Total revenues of $753,000 for third quarter, and $1,571,000 for first nine months of 2025, from sales and collaborative research agreement - ...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© ACCESSWIRE
14.10.2025
HUMA
LISTED
NASDAQ
D. Boral Capital Acted as Exclusive Placement Agent to Humacyte (Nasdaq: HUMA) in Connection with its $60,000,000 Registered Direct Offering
News Preview
NEW YORK CITY, NEW YORK / ACCESS Newswire / October 14, 2025 / On October 7, 2025, Humacyte, Inc. (Nasdaq:HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, announced that it entered into a securities purchase agreement with certain fundamental institutional...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© Globe Newswire
06.10.2025
HUMA
LISTED
NASDAQ
Humacyte Announces Publication of Long-Term Results for Ukrainian Patients Treated in Real-World Combat Setting with Symvess™
News Preview
- Results published in Oxford Academic’s Military Medicine Journal -...
Themefolio
Profiler
Peergroup
© Globe Newswire
18.09.2025
HUMA
LISTED
NASDAQ
Humacyte Announces Publication of Preclinical Data on Use of the CTEV as a Coronary Artery Bypass Graft (CABG)
News Preview
- Results were published in JACC: Basic to Translational Science -...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.09.2025
HUMA
LISTED
NASDAQ
Humacyte Announces Publication of Outcomes for Patients with Hospital-Acquired Vascular Complications Treated with Symvess™
News Preview
- Results were published in the Journal of Vascular Surgery -...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.08.2025
HUMA
LISTED
NASDAQ
Humacyte Announces Second Quarter 2025 Financial Results and Provides Business Update
News Preview
- Total revenues of $301,000 for quarter, and $818,000 for first six months of 2025, from sales and collaborative research agreement -...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.06.2025
HUMA
LISTED
NASDAQ
Results from Humacyte’s V007 Pivotal Phase 3 AV Access Study Highlighted by Presentation at the Society for Vascular Surgery Meeting
News Preview
Benefits of Humacyte’s Acellular Tissue Engineered Vessel Over Autologous Arteriovenous Fistula (AVF) in High-Risk Patients with End-Stage Kidney Disease Observed in Data Presented in Plenary Session Benefits of Humacyte’s Acellular Tissue Engineered Vessel Over Autologous Arteriovenous Fistula (AVF) in High-Risk Patients with End-Stage Kidney Dise...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.05.2025
HUMA
LISTED
NASDAQ
Humacyte to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference at Nasdaq
News Preview
DURHAM, N.C., May 19, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that Laura Niklason, M.D., Ph.D., Founder, President, and Chief Executive Officer, will present at the H.C. Wainwright...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.05.2025
HUMA
LISTED
NASDAQ
Humacyte Announces First Quarter 2025 Financial Results and Provides Business Update
News Preview
- Commenced market launch and first commercial sales of Symvess™ (acellular tissue engineered vessel-tyod) for the treatment of extremity vascular trauma -...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.05.2025
HUMA
LISTED
NASDAQ
Humacyte to Present First Quarter Financial Results and Provide Corporate Update on May 13, 2025
News Preview
DURHAM, N.C., May 09, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, will release its financial results for the quarter ended March 31, 2025, on Tuesday, May 13, 2025. Management will host a webcast and conf...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Globe Newswire
28.03.2025
HUMA
LISTED
NASDAQ
Humacyte Announces Fourth Quarter and Year End 2024 Financial Results and Provides Business Update
News Preview
- Received U.S. Food and Drug Administration (FDA) approval of Symvess™ (acellular tissue engineered vessel-tyod) for the treatment of extremity vascular trauma -...
Themefolio
Profiler
Peergroup
© Globe Newswire
26.03.2025
HUMA
LISTED
NASDAQ
Humacyte, Inc. Announces Pricing of Public Offering of Common Stock
News Preview
DURHAM, N.C., March 25, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the pricing of an underwritten public offering of 25,000,000 shares of its common stock at a public offering price of...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.03.2025
HUMA
LISTED
NASDAQ
Humacyte Announces Publication of the Budget Impact Model (BIM) for Symvess™ (acellular tissue engineered vessel-tyod) in the Journal of Medical Economics
News Preview
– Symvess is a first-in-class bioengineered human tissue designed to be a universally implantable vascular conduit for use in arterial replacement and repair –...
Themefolio
Profiler
Peergroup
© BusinessWire
06.03.2025
HUMA
LISTED
NASDAQ
Trestle Bio Announces Research Collaboration with Humacyte
News Preview
Trestle Biotherapeutics, Inc., today announced a research collaboration with Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale. Trestle Bio is a preclinical stage company developing bioengineered kidney tissues for patients suffering f...
Themefolio
Profiler
Peergroup
© Globe Newswire
21.01.2025
HUMA
LISTED
NASDAQ
Humacyte Announces Planned IND Filing in 2025 to Support First-In-Human Clinical Study of Small-Diameter ATEV™ for Coronary Artery Bypass Grafting
News Preview
– Plans for filing an IND was agreed with the FDA in a recent meeting –...
Themefolio
Profiler
Peergroup
© BusinessWire
17.01.2025
HUMA
LISTED
NASDAQ
HUMA Investors Have Opportunity to Lead Humacyte, Inc. Securities Fraud Lawsuit with the Schall Law Firm
News Preview
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Humacyte, Inc. (“Humacyte” or “the Company”) (NASDAQ: HUMA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Invest...
Themefolio
Profiler
Peergroup
© BusinessWire
17.01.2025
HUMA
LISTED
NASDAQ
HUMA Deadline: Rosen Law Firm Urges Humacyte, Inc. (NASDAQ: HUMA) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
News Preview
Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action on behalf of purchasers of securities of Humacyte, Inc. (NASDAQ: HUMA) between May 10, 2024 and October 17, 2024. Humacyte describes itself as a company that “engages in the development and manufacture of off-the-shelf, implantable, and bio...
Themefolio
Profiler
Peergroup
© BusinessWire
15.01.2025
HUMA
LISTED
NASDAQ
Deadline Soon: Humacyte, Inc. (HUMA) Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
News Preview
The Law Offices of Frank R. Cruz reminds investors of the upcoming January 17, 2025 deadline to participate as a lead plaintiff in the securities fraud class action lawsuit filed on behalf of investors who acquired Humacyte, Inc. (“Humacyte” or the “Company”) (NASDAQ: HUMA) securities between May 10, 2024 and October 17, 2024, inclusive (the “Clas...
Themefolio
Profiler
Peergroup
© BusinessWire
31.12.2024
HUMA
LISTED
NASDAQ
Kirby McInerney LLP Urges Investors in Humacyte, Inc. to Inquire About Their Rights in Class Action Lawsuit
News Preview
The law firm of Kirby McInerney LLP reminds investors that a class action lawsuit has been filed in the U.S. District Court for the Middle District of North Carolina on behalf of those who acquired Humacyte, Inc. (“Humacyte” or the “Company”) (NASDAQ:HUMA) securities between May 10, 2024, through October 17, 2024 (“the Class Period”). Investors ha...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.12.2024
HUMA
LISTED
NASDAQ
Humacyte Announces FDA Approval of SYMVESS™ (acellular tissue engineered vessel-tyod) for the Treatment of Extremity Vascular Trauma
News Preview
– SYMVESS is a first-in-class bioengineered human tissue designed to be a universally implantable vascular conduit for use in arterial replacement and repair –...
Themefolio
Profiler
Peergroup
© BusinessWire
02.12.2024
HUMA
LISTED
NASDAQ
Kirby McInerney LLP Reminds Humacyte (HUMA) Investors of Class Action Filing and Encourages Investors to Contact the Firm
News Preview
The law firm of Kirby McInerney LLP reminds investors that a class action lawsuit has been filed in the U.S. District Court for the North Carolina Middle District on behalf of those who acquired Humacyte, Inc. (“Humacyte” or the “Company”) (NASDAQ: HUMA) securities during the period of May 10, 2024 to October 17, 2024, inclusive (“the Class Period...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.12.2024
HUMA
LISTED
NASDAQ
Humacyte to Present at the Piper Sandler 36th Annual Healthcare Conference
News Preview
DURHAM, N.C., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, today announced that Laura Niklason, M.D., Ph.D., Founder, President, and Chief Executive Officer, will participate in a fireside chat pr...
Themefolio
Profiler
Peergroup
© BusinessWire
01.12.2024
HUMA
LISTED
NASDAQ
HUMA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Humacyte, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
News Preview
Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Humacyte, Inc. (“Humacyte” or “the Company”) (NASDAQ: HUMA) and certain of its officers.
Class Definition
This lawsuit seeks to recover damages against Defendants for alleged vio...
Themefolio
Profiler
Peergroup
© BusinessWire
22.11.2024
HUMA
LISTED
NASDAQ
HUMA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Humacyte, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
News Preview
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Humacyte, Inc. (“Humacyte” or “the Company”) (NASDAQ: HUMA) and certain of its officers.
Class Definition
This lawsuit seeks to recover damages against Defendants for alleged viol...
Themefolio
Profiler
Peergroup
© BusinessWire
22.11.2024
HUMA
LISTED
NASDAQ
Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Humacyte, Inc. (HUMA)
News Preview
Law Offices of Howard G. Smith reminds investors of the upcoming January 17, 2025 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Humacyte, Inc. (“Humacyte” or the “Company”) (NASDAQ: HUMA) securities between May 10, 2024 and October 17, 2024, inclusive (the “Class Period”).
Investors suffering los...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.11.2024
HUMA
LISTED
NASDAQ
Humacyte to Present Efficacy and Safety Results from V007 Phase 3 AV Access Clinical Trial at the 51st Annual Symposium on Vascular and Endovascular Issues, Techniques and Horizons (VEITH)
News Preview
DURHAM, N.C., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, today announced that it will present Phase 3 results from a clinical study comparing efficacy and safety of Humacyte's acellular tissue e...
Themefolio
Profiler
Peergroup
© BusinessWire
21.11.2024
HUMA
LISTED
NASDAQ
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Humacyte, Inc. (HUMA)
News Preview
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming January 17, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Humacyte, Inc. (“Humacyte” or the “Company”) (NASDAQ: HUMA) securities between May 10, 2024 and October 17, 2024, inclusive (the “Cl...
Themefolio
Profiler
Peergroup
© BusinessWire
20.11.2024
HUMA
LISTED
NASDAQ
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Humacyte
News Preview
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Humacyte, Inc. (“Humacyte” or the “Company”) (NASDAQ: HUMA) and reminds investors of the January 17, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Faruqi &...
Themefolio
Profiler
Peergroup
© BusinessWire
20.11.2024
HUMA
LISTED
NASDAQ
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Humacyte, Inc. (HUMA) Investors
News Preview
The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of persons and entities that purchased or otherwise acquired Humacyte, Inc. (“Humacyte” or the “Company”) (NASDAQ: HUMA) securities between May 10, 2024 and October 17, 2024, inclusive (the “Class Period”). Humacyte investors have until January 17, 2025...
Themefolio
Profiler
Peergroup
© BusinessWire
20.11.2024
HUMA
LISTED
NASDAQ
HUMA Investors Have Opportunity to Lead Humacyte, Inc. Securities Fraud Lawsuit with the Schall Law Firm
News Preview
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Humacyte, Inc. (“Humacyte” or “the Company”) (NASDAQ: HUMA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Invest...
Themefolio
Profiler
Peergroup
© BusinessWire
19.11.2024
HUMA
LISTED
NASDAQ
Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Humacyte, Inc. (HUMA) Investors
News Preview
The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed in the U.S. District Court for the North Carolina Middle District on behalf of those who acquired Humacyte, Inc. (“Humacyte” or the “Company”) (NASDAQ: HUMA) securities during the period of May 10, 2024 to October 17, 2024, inclusive (“the Class Period”). Inve...
Themefolio
Profiler
Peergroup
© BusinessWire
19.11.2024
HUMA
LISTED
NASDAQ
Rosen Law Firm Urges Humacyte, Inc. (NASDAQ: HUMA) Stockholders with Large Losses in Excess of $100K to Contact the Firm for Information About Their Rights
News Preview
Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers of securities of Humacyte, Inc. (NASDAQ: HUMA) between May 10, 2024 and October 17, 2024. Humacyte describes itself as a company that “engages in the development and manufacture of off-the-shelf, implantable, and bioengineer...
Themefolio
Profiler
Peergroup
© BusinessWire
19.11.2024
HUMA
LISTED
NASDAQ
INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Humacyte, Inc. (HUMA) Investors
News Preview
Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Humacyte, Inc. (“Humacyte” or the “Company”) (NASDAQ: HUMA) securities between May 10, 2024 and October 17, 2024, inclusive (the “Class Period”). Humacyte investors have until January 17, 2025 to file a lead plaintiff motion....
Themefolio
Profiler
Peergroup
© BusinessWire
18.11.2024
HUMA
LISTED
NASDAQ
HUMA CLASS ACTION NOTICE: Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against Humacyte, Inc.
News Preview
Glancy Prongay & Murray LLP (“GPM”), announces that it has filed a class action lawsuit in the United States District Court for the Middle District of North Carolina, captioned Cutshall v. Humacyte, Inc., et al., Case No. 1:24-cv-00954, on behalf of persons and entities that purchased or otherwise acquired Humacyte, Inc. (“Humacyte” or the “Co...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.11.2024
HUMA
LISTED
NASDAQ
Humacyte Third Quarter 2024 Financial Results and Business Update
News Preview
- FDA review of acellular tissue engineered vessel (ATEV™) BLA for the Treatment of Vascular Trauma is ongoing -...
Themefolio
Profiler
Peergroup
© BusinessWire
06.11.2024
HUMA
LISTED
NASDAQ
The Law Offices of Frank R. Cruz Continues Its Investigation of Humacyte, Inc. (HUMA) on Behalf of Investors
News Preview
The Law Offices of Frank R. Cruz continues its investigation on behalf of Humacyte, Inc. (“Humacyte” or the “Company”) (NASDAQ:HUMA) investors concerning the Company and its officers’ possible violations of federal securities laws.
If you are a shareholder who suffered a loss, click here to participate.
On August 9, 2024, after market hours, Hum...
Themefolio
Profiler
Peergroup
© Globe Newswire
28.10.2024
HUMA
LISTED
NASDAQ
Humacyte Announces Presentation of Positive Results from V007 Phase 3 AV Access Clinical Trial at the American Society of Nephrology’s Kidney Week 2024
News Preview
– ATEV™ demonstrated superiority at six and 12 months (co-primary endpoints) compared to autogenous fistula, the current standard of care for hemodialysis access –...
Themefolio
Profiler
Peergroup
© BusinessWire
24.10.2024
HUMA
LISTED
NASDAQ
Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Humacyte, Inc. (HUMA)
News Preview
The law firm of Kirby McInerney LLP is investigating potential claims against Humacyte, Inc. (“Humacyte” or the “Company”) (NASDAQ: HUMA). The investigation concerns whether Humacyte and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices.
[Click here to learn more about the inv...
Themefolio
Profiler
Peergroup
© BusinessWire
23.10.2024
HUMA
LISTED
NASDAQ
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Humacyte, Inc. (HUMA) on Behalf of Investors
News Preview
Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Humacyte, Inc. (“Humacyte” or the “Company”) (NASDAQ: HUMA) investors concerning the Company’s possible violations of the federal securities laws.
If you suffered a loss on your Humacyte inve...
Themefolio
Profiler
Peergroup
© Globe Newswire
23.10.2024
HUMA
LISTED
NASDAQ
Humacyte to Host Virtual KOL Event on the Use of Acellular Tissue Engineered Vessel (ATEV™) for AV Access in Hemodialysis on October 31, 2024
News Preview
DURHAM, N.C., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, today announced that it will host a virtual KOL event on Thursday, October 31, 2024 at 8:00 AM ET. To register, click here....
Themefolio
Profiler
Peergroup
© BusinessWire
23.10.2024
HUMA
LISTED
NASDAQ
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Humacyte, Inc. (HUMA) on Behalf of Investors
News Preview
Law Offices of Howard G. Smith announces an investigation on behalf of Humacyte, Inc. (“Humacyte” or the “Company”) (NASDAQ: HUMA) investors concerning the Company’s possible violations of federal securities laws.
On August 9, 2024, after market hours, Humacyte disclosed that the FDA needed “additional time to complete its review of its Biologic...
Themefolio
Profiler
Peergroup
© BusinessWire
23.10.2024
HUMA
LISTED
NASDAQ
The Law Offices of Frank R. Cruz Announces Investigation of Humacyte, Inc. (HUMA) on Behalf of Investors
News Preview
The Law Offices of Frank R. Cruz announces an investigation of Humacyte, Inc. (“Humacyte” or the “Company”) (NASDAQ: HUMA) on behalf of investors concerning the Company’s possible violations of federal securities laws.
If you are a shareholder who suffered a loss, click here to participate.
On August 9, 2024, after market hours, Humacyte disclos...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.10.2024
HUMA
LISTED
NASDAQ
Humacyte Announces Pricing of $30.0 Million Registered Direct Offering
News Preview
DURHAM, N.C., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, today announced that it entered into a securities purchase agreement with an institutional investor to purchase approximately $30.0 milli...
Themefolio
Profiler
Peergroup
© Globe Newswire
26.09.2024
HUMA
LISTED
NASDAQ
Humacyte to Host Virtual KOL Event to Discuss Case Studies on the Use of Acellular Tissue Engineered Vessel (ATEV™) in Vascular Trauma Treatment on September 30, 2024
News Preview
DURHAM, N.C., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, today announced it will host a virtual KOL event on Monday, September 30, 2024 at 8:00 AM ET. To register, click here....
Themefolio
Profiler
Peergroup
© Globe Newswire
09.08.2024
HUMA
LISTED
NASDAQ
Humacyte Announces FDA Communication of Additional Time Required to Complete Review of acellular tissue engineered vessel (ATEV™) BLA for the Treatment of Vascular Trauma
News Preview
– 2nd quarter conference call to be held Tuesday, August 13th, at 8:30 a.m. ET –...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.05.2024
HUMA
LISTED
NASDAQ
Humacyte First Quarter 2024 Financial Results and Business Update
News Preview
-Biologics License Application (BLA) for HAV™ Accepted by FDA-...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
